↓ Skip to main content

Dove Medical Press

Fixed-combination treatments for intraocular hypertension in Chinese patients – focus on bimatoprost-timolol

Overview of attention for article published in Drug Design, Development and Therapy, May 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)
  • Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

twitter
1 X user
wikipedia
1 Wikipedia page
googleplus
1 Google+ user

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
37 Mendeley
Title
Fixed-combination treatments for intraocular hypertension in Chinese patients – focus on bimatoprost-timolol
Published in
Drug Design, Development and Therapy, May 2015
DOI 10.2147/dddt.s80338
Pubmed ID
Authors

Yuan Fang, Zhihong Ling, Xinghuai Sun

Abstract

Glaucoma is a common eye disease that can lead to irreversible vision loss if left untreated. The early diagnosis and treatment of primary open-angle glaucoma is challenging, and visual impairment in Chinese glaucoma patients is a serious concern. Most of these patients need more than one topical antiglaucoma agent to control their intraocular pressures (IOPs). In the People's Republic of China, the daily cost of different glaucoma medication varies greatly, and the treatment habits differ throughout the country. Prostaglandin analogs (PGAs) are recommended as first-line monotherapy, because of their efficacy and low risk of systemic side effects. Fixed-combination drops, particularly PGA-based fixed combinations, have recently been developed and used in patients with progression or who have failed to achieve their target IOPs. Here, we reviewed the current literature on the use of bimatoprost-timolol fixed combination (BTFC) in the People's Republic of China. BTFC has achieved good efficacy and tolerability in Chinese clinical trials. In addition, BTFC is more cost effective compared with other fixed combinations available in the People's Republic of China. Fixed-combination drops may offer benefits, such as keeping the ocular surface healthy, convenience of administration, and improvement in long-term adherence and quality of life. Therefore, BTFC has great potential for the treatment of Chinese glaucoma patients. However, the long-term efficacy of BTFC, comparisons of BTFC with other fixed-combination drugs, and treatment adherence and persistence with treatment in Chinese patients are unknown and will require further study.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 3%
Unknown 36 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 6 16%
Other 5 14%
Student > Bachelor 4 11%
Student > Ph. D. Student 3 8%
Student > Doctoral Student 2 5%
Other 5 14%
Unknown 12 32%
Readers by discipline Count As %
Medicine and Dentistry 17 46%
Nursing and Health Professions 3 8%
Pharmacology, Toxicology and Pharmaceutical Science 2 5%
Biochemistry, Genetics and Molecular Biology 1 3%
Agricultural and Biological Sciences 1 3%
Other 3 8%
Unknown 10 27%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 March 2020.
All research outputs
#7,205,295
of 25,374,917 outputs
Outputs from Drug Design, Development and Therapy
#467
of 2,268 outputs
Outputs of similar age
#79,824
of 278,920 outputs
Outputs of similar age from Drug Design, Development and Therapy
#21
of 99 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 278,920 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 99 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.